Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
12.52
-0.18 (-1.42%)
Sep 17, 2026, 4:00 PM EDT - Market closed
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$543,817
Profits / Employee
-$526,917
Market Cap
364.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsENTA News
- 1 day ago - Enanta Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 days ago - Enanta Pharmaceuticals Transcript: 2026 Global Healthcare Conference - Transcripts
- 16 days ago - Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire
- 5 weeks ago - Enanta Pharmaceuticals Earnings release: Q3 2026 - Filings
- 5 weeks ago - Enanta Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 2 months ago - Enanta announces European Commission approval of Maviret - TheFly
- 2 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - Business Wire